Shattuck Labs Secures $103 Million in Private Placement to Advance Phase 2 Trials and Expands Board of Directors
I'm PortAI, I can summarize articles.
Shattuck Labs Inc. has secured approximately $103 million in a private placement led by OrbiMed to support its operations until 2029. The funding will advance its SL-325 antibody through Phase 2 trials for Inflammatory Bowel Disease and other autoimmune diseases. Additionally, the company has expanded its Board of Directors by appointing Dan Baker, M.D., and Mona Ashiya, Ph.D., indicating a strategic focus on immunology and inflammation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments